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Summary. The immunosuppressant drug cyclosporin A 
(CsA) is known to cause reduction in number, DNA 
synthesis and function of Langerhans cells (LC). Since 
also the differentiation of LC is known to be hampered 
in conditions of acquired immunodeficiency not due to 
drugs, we investigated whether this occurs with CsA. 
Rats were injected subcutaneously with CsA (5, 10 and 
50 mg.kg-l.d-l) for three weeks; the skin was analyzed 
by Ia immunohistochemistry and by electron 
microscopy. Epidermal immunolabeled cells were 
1553.5 (mean I SEM) per 100 basa1 keratinocytes in 
untreated controls and 8.7511.3, 4.7551.0 and 1.751.2 
upon increasing doses of CsA (pe0.01). By electron 
microscopy, monocytoid cells with deep invaginations of 
the plasma membrane and roundish LC poor in Birbeck 
granules appeared in the epidermis upon treatment. The 
results suggest that CsA inhibits the differentiation of 
LC precursors in the epidermis and that this can in part 
explain the selective increase in the risk of skin vira1 
disease and cancer in chronically treated patients. 
Key words: Differentiation, Electron microscopy, 
Irnrnunohistochemistry, Monocytes 
lntroduction 
Cyclosporin A (CsA) is  a powerful immuno- 
suppressant drug widely used in clinics to prevent 
undesired cell-mediated immune responses such as 
rejection of grafted organs and tissues, graft versus host 
and autoimmune diseases (Weil, 1984; Feutren, 1993). 
The use of CsA is by no means devoid of drawbacks. 
Wide clinical evidence indicates that patients subjected 
to Jong term (more than 5 years) treatment with CsA 
experience increased risk of skin warts and skin 
malignancies; the latter are the prevalent type of 
malignancies in these patients. Although the increased 
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risk of cancer is common among al1 immunosuppressed 
patients, CsA is burdened by a higher risk of skin, rather 
than non-skin cancer if compared with other types of 
immunosuppressant therapy (Gruber et al., 1994; 
Hepbum et al., 1994; Thiel et al., 1994; London et al., 
1995; Barba et al., 1997; Frezza et al., 1997; Danta1 et 
al., 1998). The increase in the risk of cancer upon CsA 
therapy is dose-dependent (Danta1 et al., 1998). A 
specific effect of CsA on skin immune system might 
explain the role of this drug in skin carcinogenesis better 
than its effect on the immune system in general. 
The action of CsA depends primarily on selective 
suppression of T cell activation by inhibiting the 
transcription of several cytokine genes (Quesniaux, 
1993). A secondary mechanism of action proposed for 
CsA is an interference with the accessory function of 
antigen-presenting cells, especially epidermal 
Langerhans cells (LC). Cyclosporin A has been reported 
to inhibit the lymphocyte proliferation-stimulating 
capacity of human (Cooper et al., 1990; Dupuy et al., 
1991; Teunissen et al., 1991) and murine LC (Furue and 
Katz, 1988). It has been proposed that this inhibition 
depends on carryover of the drug at the moment of 
adding LC to lymphocytes (Péguet-Navarro et al., 1991), 
but other investigations have shown that CsA has a 
direct, inhibiting effect on alloantigen presentation by 
LC (Demidem et al., 1991). 
Cyclosporin A treatment influences negatively the 
number of major histocompatibility complex - class 11 
(MHC-11)-positive LC in human epidermis (Jontell et al., 
1988; Gupta et al., 1989; Horrocks et al., 1990; Bergfelt, 
1993; Bergfelt et al., 1993) and gingival epithelium 
(Niimi et al., 1990). One group reported no effect of CsA 
on the number of LC in the epidermis of human skin 
grafts onto nude mice (Urabe et al., 1989; Kanitakis et 
al., 1990), but this same group found decreased synthesis 
of DNA by LC in the same experimental conditions 
(Haftek et al., 1991). It cannot be excluded that the 
results of these experiments depend on metabolic 
peculiarities of the recipient species, since LC in the 
mouse epidermis decrease upon topical, but not systemic 
administration of CsA (Halliday et al., 1986). A hint that 
CsA possibly affects the proliferation and differentiation 
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of cells of Langerhans lineage comes from the efficacy 
of this drug for  the therapy of LC histiocytosis 
(Mahmoud et al., 1991; Arico et al., 1995; Korholz et al., 
1997). 
Reduced cell-mediated immune responses in human 
oral mucosa upon HIV infection (Riccardi et al., 1990; 
Romagnoli et al., 1997) and in mouse skin upon 
ultraviolet B irradiation (Bacci et al. ,  1998) are 
associated with inhibited differentiation of LC in situ; 
however, despite the above cited reports that chronic 
administration of CsA causes reduction in number of 
MHC-11-positive LC, the effects of this drug on the 
differentiation of LC in vivo have not yet been explored. 
To address this issue, we have studied the morphological 
and immunophenotypical differentiative responses of rat 
epidermal LC to protracted treatment with CsA at 
therapeutic and toxic doses. 
Materials and methods 
Animals 
Fifteen male Wistar rats weighting 250-300 g were 
used in this study in agreement with the Italian law and 
the international standards of laboratory animal care. 
Before entering the experiments the animals were 
accustomed to the laboratory for 5-7 days; they were 
kept at 22-25 "C with natural illumination, on a standard 
diet with free access to water. 
Treatment 
Three groups of 4 rats each were treated daily for 3 
weeks with subcutaneous injections of CsA (generously 
provided by Sandoz, Basel, Switzerland) at doses of 5, 
10 and 50 mg per kg body weight respectively. The drug 
was disolved in cremophor and suspended in saline 
before use. A further group of 3 rats was injected with 
saline alone, as control. Al1 rats were weighted and 
sacrified by cervical dislocation after the last injection 
and the abdominal skin was harvested for microscopical 
analyses. 
Assay of CsA plasma concentrations 
Blood samples were collected from the tail vein of 
treated rats into heparinized glass tubes before sacrifice. 
Upon centrifugation to separate plasma, CsA 
concentration was determined by radioimmunoassay 
using a commercial kit (Sandoz). 
Light and electron microscopy 
Skin fragments from each rat were fixed in 4% 
glutaraldehyde in 0.1 mollliter cacodylate buffer, pH 7.4, 
osmicated and embedded in Epon 812. Semithin sections 
(-lpm) perpendicular to epidermal surface were stained 
with alkaline toluidine blue and used for morphometry 
as follows. The thickness of epidermis was measured 
with a calibrated ruler 5 to 10  times per section, at 
regularly spaced intervals, on one section per animal, 
and the data were averaged to obtain the epidermal 
thickness of each animal. Thin (-70 nm) sections were 
stained with uranyl acetate and alkaline bismuth 
subnitrate (Riva, 1974) and examined in a Siemens 
Elmiskop 102 electron microscope at 80 kv. 
lmmunohistochemistry 
Skin fragments of each rat were embedded in Tissue 
Tek (Bio-Optica, Milan, Italy) and snap frozen. 
Cryosections were fixed in cold acetone and stained with 
monoclonal antibody 0 x 4  (Seralab, Crawley Down, 
Sussex), that labels Ia molecules of al1 rat strains, 
followed by indirect alkaline phosphatase-anti alkaline 
phosphatase complex (APAAP, Dako, Milan, Italy) 
which was revealed using new fuchsin (Sigma, Milan, 
Italy) as chromogen. The specificity of the immuno- 
staining was checked by omitting the first antibody or 
substituting it with an irrelevant one, which always gave 
unstained slides. For quantitative analysis, the stained 
cell bodies, containing a nucleus and overlying 100 basal 
cells were counted in five consecutive fields at x250. 
Statistics 
Each rat was assumed as a sample unit for statistics. 
Data are given as means 1 standard error; they were 
subjected to analysis of variance and Student's t test for 
unpaired values with two tails, assuming p<0.01 as 
significant. 
Results 
Cyclosporin A plasma concentrations 
The serum concentrations of CsA were 17015 
ng/mL in rats treated with 5 mg.kg-l.daK-l, 3-80110 
ng/mL in rats treated with 1 0  mg.kg- .day and 
32041518 ng/mL in rats treated with 50 mg.kgwl.day-l 
(p<0.01). Rats treated with CsA at any dose showed no 
gain in body weight, on the contrary to controls which 
underwent substantial increase in body weight in the 
same period of time. At the end of the experiments, rat 
weights were as  follow: controls, 34319 g ;  5 mg. 
kgvl.day-l CsA treated, 288I16 g; 10 mg.kg-l.day-l CsA 
treated, 273113 g; 50  mg.kg-l.day-l CsA treated, 
209110 g (p< 0.01). 
Light microscopy 
In controls, dendritic, Ia-positive cells were 15 1 3.5 
per 100 basal keratinocytes and were located in the basal 
and suprabasal epidermal layers. These cells undenvent 
progressive reduction in number with increasing doses of 
CsA, becomin 8 75+1.3 per 100 basal keratinocytes 
upon 5 mg.kg-$.diy-~ CsA, 4.7511.0 upon 10 mg.kg- 
l.day-l (p<0.01 versus controls) and 1.711.2 upon 50 
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mg.kg-l.day-l (pc0.01 versus controls and versus 5 
mg.kgml.day-l). The thickness of epidermis was as 
follows: controls, 121220 pm; 5 mg.Kp-l.day-l CsA 
treated, lll+ll pm; 10 m .Kg-l.dayb CsA treated, f 88225 pm; 50 mg.Kg-l.day- CsA treated, 92114 pm (p 
n.s.). 
Electron microscopy 
Most LC of controls were well differentiated 
morphologically (Fig. 1); a few cells, recognized as LC 
because they contained rare Birbeck granules, were 
apparently devoid of dendrites and had narrow 
invaginations of the plasma membrane into the 
superficial cytoplasm (Fig. 2). Very few roundish, 
monocyte-like cells were sometimes found interspersed 
among keratinocytes of the basal layers. 
Very few LC were well differentiated morpho- 
logically in the epidermis of al1 treated rats. Conversely, 
many LC were roundish in shape, had few membrane- 
bound organelles, severa1 lysosomes and numerous 
invaginations of the plasma membrane in the superficial 
cytoplasm (Fig. 3). Moreover, the basal epidermal layer 
of treated rats at any dose hosted numerous monocyte- 
like cells with narrow, deep invaginations of the plasma 
membrane in the superficial cytoplasm (Fig. 4); some of 
these cells were in contact with lymphocytes (Fig. 5). 
Discussion 
In this study we found that systemic treatment with 
CsA induces in the rat skin a dose-dependent reduction 
in the number of MHC-11-positive, dendritic LC and 
conversely the appearance of monocytoid ceils with deep 
invaginations of the plasma membrane. 
We found LC in control rats troughout basal and 
suprabasal nucleated cell layers, as is known for mice 
(Baker et al., 1983; Mackenzie and Bickenbach, 1985; 
Bacci et al., 1998), cattle (Khalil et al., 1982), cats 
(Marcha1 et al., 1997), sheep (Townsend et al., 1997) and 
humans (see, e.g., Murphy et al., 1985; Régnier et al., 
1997). 
~~munohis tochemica l  data are compatible with a 
reduction in number of L C  and with a loss  of Ia 
molecules by preserved LC as well. It is reasonable to 
assume that both mechanisms were at work, since the 
finding of Birbeck granules containing LC was less easy, 
but not exceptional at electron microscopy even upon the 
highest dosis of CsA, on the contrary IÓ  a reduition of 
around 90% of Ia-labeled cells in the same conditions. 
These results are in line with the data reported by De 
Waal et al. (1992, 1996) on interdigitating, dendritic 
Flg. 1. A Langerhans cell of a control rat is dendritic in shape and rich in 
organelles. The arrows point to Birbeck granules. Electron microscopy, 
x 10,000 
Flg. 2. Langerhans cell of a control rat, roundish in shape with rare 
granules (arrowead) and many infoldings of the plasma membrane. 
x 12,000. Inset: detail of Birbeck granule (arrowead). x 21,600 
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cells in the CsA-treated rat thymus. 
Most LC upon high doses of CsA had a roundish 
cell body. Since they had no increase in organelle 
content and MHC-11 expression they cannot be 
interpreted as cells moving away from the epidermis 
during final differentiation. On the other hand, they 
showed no sign of alteration, such as cytoplasmic 
vacuolization, mitochondrial swelling or disruption of 
membrane-bound organelles, so they did not appear as 
degenerating. Rather, the similarity of these cells to 
those found in humans in conditions of hampered 
differentiation of LC within epidermis (Riccardi et al., 
1990; Mori e t  al., 1994) and in mice undergoing 
recovery of L C  within epidermis upon ultraviolet 
irradiation (Bacci et al., 1998) suggests that al1 these 
cel ls  are  immature elements  along the line of 
differentiation to LC (Bani et al., 1988; Bani and 
Giannotti, 1989). The deep, narrow invaginations of the 
plasma membrane in several LC and in monocytoid cells 
without Birbeck granules  a re  suggestive of 
internalization of plasma membrane eventually leading 
to the formation of Birbeck granules as reported in 
previous studies on mycosis fungoides and hystiocytosis 
X (Hashimoto and Tarnowsky, 1968; Bani et al., 1988). 
The cells found in the epidermis upon CsA have no 
features of macrophages, therefore cannot be interpreted 
as corresponding to the macrophages expressing CD36 
and MHC-11 molecules, described in human skin after 
ultraviolet-irradiation (Cooper et al., 1985, 1986). 
The concomitance of numerous immature cells of 
monocyte-Langerhans lineage and few mature, Ia- 
expressing LC in the epidermis upon CsA suggests that 
LC precursors are still allowed to reach the epidermis 
but are prevented from achieving full differentiation. 
Since L C  are subjected to  continuous turnover 
(Ghaznawie et al., 1999), the decrease in number of 
mature L C  would follow the lack of sufficient 
replacement and normal - or perhaps even enhanced - 
clearance of mature cells during the three weeks of 
treatment. 
We should like to conclude that CsA impairs 
primarily the maturation of cells of Langerhans lineage 
in the rat epidermis and only secondarily may affect the 
expression of MHC-11 molecules by LC pre-existing in 
the epidermis. These effects might be either direct or 
mediated by alterations of the epidermal micro- 
environment, such as keratinocyte atrophy (Mori et al., 
1994), or both. The alterations reported here upon CsA 
are in part similar to those obsewed in the oral mucosa 
of humans with HIV infection (Riccardi et al., 1990; 
Romagnoli et al., 1997) and in the mouse epidermis 
upon agents damaging mature LC (Bacci et al., 1998). 
Flg. 3. A Langerhans cell of a rat treated with 10 mg.kg-1 CsA is 
roundish and poor in membrane bound organelles but contains several 
lysosomes (arrowheads) and extensive infoldings of the plasma 
membrane (double arrowheads). The arrows point to Birbeck granules. 
Electron microscopy, x 20,000 
Flg. 4. A monocyte-like cell in the epidermis of a rat treated with 10 
mg.kg-1 CsA is poor in organelles and has no Birbeck granules, but 
contains infoldings of the plasma membrane (double arrowhead). 
Electron microscopy, x 13,000 
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Flg. 5. Two monocyte-like cells in the epidermis of a rat treated with 10 
mg.kg-1 CsA contain infoldings of the plasma membrane and are in 
contact with a lymphocyte (asterisk). Electron microscopy, x 11,000 
The block of expression of  MHC-11 molecules is  
especially worth noting, since these molecules are 
necessary for the presentation of antigens to CD4- 
positive lymphocytes. It seems therefore reasonable that 
the reduction in the number of well differentiated LC 
upon CsA treatment leads to depression of local immune 
responses, such as those against virus-infected or 
neoplastic epidermal cells. This would explain the 
selective sensitivity of the skin to virus infection and 
neoplasia that is observed dose-dependently in humans 
subjected to chronic CsA treatment (Danta1 et al., 1998). 
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